REITWAVE.COM Institutional Equity Tear Sheet Generator
Download Vector PDF Export Model (CSV)
REITWAVE.COM | INSTITUTIONAL REAL ESTATE RESEARCH
AS OF: OCTOBER 24, 2026  |  10Y TREASURY: 4.99%  |  SIC 6798

HEALTHPEAK PROPERTIES, INC. ($DOC)

Sector: Healthcare & Medical Office  •  Exchange / CIK: NYSE / 0000765880  •  Properties: 150 Assets
Trading at a 8.2% discount to NAV
Safety Score: 78/100 (Safe)  |  Credit: BBB

Live Share Price

$19.25
52W Range: $15.70 - $22.95

Valuation Multiples

14.5x P/AFFO
P/FFO: 13.4x  |  FFO/sh: $1.44

Net Asset Value (NAV)

$20.98
Prem/Disc: -8.2%  |  Cap: 6.54%

Dividend Cash Flow

5.30% Yield
$1.02/yr (Quarterly)  |  Payout: 76.7%
Balance Sheet & Debt Maturity Sentry
Net Debt to EBITDAre stands at 5.2x. Portfolio leased occupancy is 91.5% with a weighted average lease term (WALT) of 6.5 years. Senior credit rating of BBB provides institutional capital markets access for debt refinancing.
Recent Dividend Payment History (Last 6 Declarations)
Ex-Dividend Date Record / Pay Date Cash Distribution Status / Corporate Action
2026-09-30 2026-10-15 $0.2550 Regular Distribution
Representative Commercial Asset Concentrations (From SEC Form 10-K Item 2)
Commercial Asset / Property Name Location Rentable Sq Ft Occupancy Implied Asset Valuation
HEALTHPEAK PROPERTIES, INC. Flagship Commercial Portfolio United States Nationwide 18,750,000 sq ft (implied) 91.5% $3,147,000,000
Quantitative Risk & Benchmark Performance (QuantStats • VNQ)
Empirical 252-day trading window compared to Vanguard Real Estate ETF (VNQ) benchmark
METHODOLOGY: QUANTSTATS / CAPM
Beta vs VNQ
1.23
High Beta (Aggressive Leverage)
Annualized Alpha (α)
+7.40%
Outperforming VNQ
Sharpe Ratio (vs VNQ)
0.3 vs 0.04
+0.26 Spread
Max Drawdown (1-Yr)
-18.1% vs -11.4%
-6.7% vs VNQ
DOC vs VNQ QuantStats Performance & Underwater Drawdown
Quantitative Risk & Return Metric DOC VNQ (Benchmark) Institutional Delta / Spread
Beta (β) vs VNQ
Covariance sensitivity to US REIT market
 1.23 1.00 +0.23 (High Beta (Aggressive Leverage))
Annualized Alpha (α)
Excess CAPM risk-adjusted performance
 +7.40% 0.00% (Baseline) Outperforming VNQ
Sharpe Ratio (Rf = 4.5%)
Annualized excess return per unit of volatility
 0.3 0.04 +0.26
Sortino Ratio
Downside semi-variance risk-adjusted return
 0.37 0.03 +0.34
Annualized Volatility (σ)
Standard deviation of daily price returns × √252
 29.9% 13.9% +16.0% (Higher Volatility)
Maximum Drawdown (1-Year)
Peak-to-trough capital decline over trailing 12M
 -18.1% -11.4% -6.7% vs VNQ
1-Year Trailing Return (CAGR)
Compounded annual growth rate
 9.7% 4.1% +5.6% Spread
R-Squared (R²) & Correlation
Statistical correlation coefficient against VNQ
 R² 0.33 Corr: 0.57 33% variance explained by VNQ
Trading Session Win Rate
Percentage of positive daily closing sessions
 48.4% 51.6% -3.2% vs Benchmark
QuantStats Analytical Synthesis: DOC displays a Beta of 1.23 relative to VNQ with 0.33 R² correlation. Annualized volatility is 29.9% (16.0% higher than VNQ at 13.9%). Trailing 12-month Alpha stands at +7.40% (Outperforming VNQ) with a Sharpe ratio of 0.30 against 0.04 for VNQ, and a maximum drawdown of -18.1%.
SEC CIK: 0000765880  |  Principal Executive Officer: Peter M. Mavoides  |  Total PEO Compensation: $7,300,000 (85:1)
Official SEC Accession: 0001579877-26-000018
CONFIDENTIAL INSTITUTIONAL TEAR SHEET • REITWAVE.COM (v1.0.0) • Data Sources: SEC EDGAR Form 10-K / DEF 14A, PR Newswire, Bloomberg/CBRE Comps. For institutional and accredited investor due diligence. Not a solicitation or investment recommendation.